5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis

Exclusion Criteria

• •Phototherapy, systemic therapy (e.g., immunosuppressants, cytostatics), systemic corticosteroids within 4 weeks
• •Topical tacrolimus or pimecrolimus within 2 weeks
• •Topical therapy (e.g., tar, topical corticosteroids) within 3 days
• •Immunocompromised (e.g., lymphoma, AIDS, Wiskott-Aldrich Syndrome) or have a history of malignant disease
• •Active acute viral skin infection (e.g. herpes simplex, herpes zoster, chicken pox), and/or clinically infected AD
• •Failure to thrive (e.g., weight or height/length below the 5th percentile) or developmental abnormalities such as head circumference less than 5th and more than 95th percentile
• •Known hypersensitivity to any ingredient of pimecrolimus cream 1% or topical corticosteroids
• •Clinical conditions other than AD that according to investigator can interfere with the evaluation